President Trump recently signed an executive order that fast-tracks the availability of psychedelic drugs for the treatment of “serious mental illnesses.” The order directs the Food and Drug Administration (FDA) to grant the Commissioner's National Priority Vouchers (CNPVs) for appropriate drugs and establish a pathway for eligible patients to gain access to investigational psychedelic drugs.
This month, biotech firm Compass Pathways plc (CMPS) received the FDA's rolling submission and review request for its NDA, based on positive phase-3 data. It was also added to the CNPV program, which entitles the company to some benefits.
